CSIMarket
 
Anika Therapeutics Inc   (ANIK)
Other Ticker:  
 
 
Price: $25.2700 $-0.17 -0.668%
Day's High: $26.19 Week Perf: -2.02 %
Day's Low: $ 25.06 30 Day Perf: 2.77 %
Volume (M): 123 52 Wk High: $ 29.26
Volume (M$): $ 3,096 52 Wk Avg: $23.19
Open: $25.37 52 Wk Low: $16.54



 Market Capitalization (Millions $) 370
 Shares Outstanding (Millions) 15
 Employees 187
 Revenues (TTM) (Millions $) 166
 Net Income (TTM) (Millions $) -83
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) 5

Anika Therapeutics Inc
Anika Therapeutics Inc is a global medical technology company that specializes in tissue-medical devices for the regenerative treatment of pain and musculoskeletal conditions. The company is headquartered in Bedford, Massachusetts, USA, and operates in over 30 countries worldwide.

Anika Therapeutics Inc was founded in 1992 by Charles H. Sherwood, Ph.D., and Richard G. Steadman, M.D, with a vision to create and deliver products that could help to promote the healing and recovery of individuals suffering from musculoskeletal injuries or diseases. The company has since grown to become a leading provider of advanced medical devices and therapies, using a range of technologies developed in-house.

The company's core product offering includes a number of tissue implants, including Orthovisc, Monovisc, and Cingal, which are designed to help alleviate the pain and mobility issues experienced by patients with osteoarthritis. These devices, which are made using high-purity hyaluronic acid, are injected into the joint to lubricate and cushion the affected area, providing long-lasting relief.

In addition to these products, Anika Therapeutics Inc also offers a range of other medical devices and solutions, such as the AmnioExcel amniotic membrane product, which is used in wound healing, and the Hyalofast scaffold, which allows for the delivery of cells and growth factors in tissue engineering repair applications.

Anika Therapeutics Inc is proud of its commitment to quality and innovation, investing heavily in research and product development to improve the efficacy and range of its medical solutions. The company has a strong record of innovation, having filed over 100 patents to date, and regularly collaborates with leading medical institutions and industry partners to develop and improve its products.

Overall, Anika Therapeutics Inc offers a diverse range of innovative, high-quality medical solutions designed to address a range of musculoskeletal concerns, improving patient outcomes and quality of life. Its focus on quality, innovation, and collaboration has helped establish it as a leader in the industry, and it continues to grow and expand its product offerings to address the evolving needs of patients worldwide.


   Company Address: 32 Wiggins Avenue Bedford 1730 MA
   Company Phone Number: 457-9000   Stock Exchange / Ticker: NASDAQ ANIK
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Anika Therapeutics Inc

Stock inducement grants impact Anika Therapeutics Inc.'s share structure and stock price



In the dynamic world of the stock market, it is crucial for investors to stay informed about the financial performance and significant developments of companies. Anika Therapeutics Inc., a global joint preservation company in early intervention orthopedics, recently reported its financial results for the October to December 31, 2023, financial period. This article will highlight key observations from the company's financial report and analyze the impact of stock inducement grants on its current share structure and stock price.
Financial Performance Overview:
During the October to December 2023 financial period, Anika Therapeutics Inc. witnessed a significant increase in revenue, reaching $43.25 million, representing a growth of 9.151% year-on-year. In comparison to its contemporaries in the Medical Equipment & Supplies sector, Anika Therapeutics Inc.'s top-line growth outpaced the industry average, highlighting its strong market position.

Shares

Anika Therapeutics Inc. Grants Stock Options as Inducement in Alignment with Share Structure and Stock Price

Published Fri, Mar 8 2024 9:01 PM UTC

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) in Context of Company's Current Share Structure and Stock Price
Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, recently announced the granting of non-statutory stock options to a newly hired non-executive employee. The grant, which covers 2,500 shares of...

Product Service News

Anika Therapeutics Enters the Rotator Cuff Augmentation Market with Novel Integrity Implant System

Published Tue, Nov 28 2023 2:02 PM UTC

Anika Therapeutics Enters the Lucrative Rotator Cuff Augmentation Market with New Integrity Implant System
Anika Therapeutics Inc, a global leader in regenerative medicine solutions, has recently announced the successful completion of the first surgeries using its Integrity Implant System for rotator cuff repairs. This novel system, based on regenerative hyaluronic acid ...

Anika Therapeutics Inc

Anika Therapeutics Inc Reveals Impressive 1.689% Revenue Surge, Pointing towards Promising Future

The stock market can be a volatile and unpredictable place, with ups and downs that can leave investors feeling uncertain. However, there are times when the numbers align and a company's performance shows great potential. Anika Therapeutics Inc is one such company that has caught the attention of many investors. Despite the recent deficit, there are optimistic signs that suggest a bright future lies ahead.
In the most recent fiscal period, Anika Therapeutics Inc reported a deficit per share of $-0.45, an increase from the $-0.29 per share deficit experienced a year ago. While this increase might initially raise concerns, it is important to note that growth often comes with some temporary setbacks. It's crucial to look at the bigger picture, and Anika Therapeutics Inc's strong revenue growth is a promising indicator.

Anika Therapeutics Inc

Anika Therapeutics Inc Reports Double-Digit Revenue Growth in Second Quarter of 2023



Anika Therapeutics Inc, a renowned company in the Medical Equipment & Supplies sector, recently reported its financial results for the period ending June 30, 2023. The results demonstrate significant improvements in various key metrics, such as earnings per share (EPS) and revenue. This article will delve into the details of the financial results and provide context by analyzing the company's stock performance.
Financial Results:
1. Earnings per Share (EPS):
In June 2023, Anika Therapeutics Inc reduced its loss per share to $-0.19 compared to $-0.20 in the previous year. This improvement shows the company's progress in managing its losses and moving towards profitability. Additionally, EPS increased from $-0.71 in the previous financial reporting period, indicating positive growth.






 

Anika Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com